Focus on Immunizations

Back to articles

Investigational herpes zoster vaccine is effective in patients aged 70 years or older

KEY POINT

GlaxoSmithKline’s investigational vaccine was found to be highly effective at preventing shingles and postherpetic neuralgia in patients aged 70 years or older, according to results of a Phase III trial published in the New England Journal of Medicine.

SOURCES

Cunningham AL, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–32.

Neuzil KM, et al. Preventing shingles and its complications in older persons. N Engl J Med. 2016;375(11):1079–80.